Across Europe, cancer services are undergoing a quiet but profound transformation. The shock of the COVID‑19 pandemic exposed how fragile routine diagnosis and treatment pathways could be when hospitals focused on emergency care, cancelled screenings, and deferred procedures. In the years since, both the European Union and individual member states have moved from crisis management toward a more strategic reshaping of cancer care, aiming not only to clear backlogs but also to build a system that is faster, fairer, and better prepared for future shocks. At the heart of this reform is a mix of top‑down EU‑level coordination, national‑level health‑system changes, and practical innovations in digital tools, workforce organisation, and access to medicines.

    The European Union has positioned itself as a coordinator rather than a direct provider of cancer care, using the “Europe’s Beating Cancer Plan” as its flagship platform. Launched in 2021, this plan bundles prevention, early detection, treatment, and life‑after‑cancer actions into a single policy umbrella, backed by approximately 4 billion euros drawn from various EU funds. Member states are encouraged not always required to align their national cancer strategies with EU‑recommended standards, particularly in areas such as tobacco control, alcohol regulation, cancer screening coverage, and digital health infrastructure. The idea is to create a common “floor” of cancer‑care quality across the continent, so that no country or region falls too far behind simply because of weaker national planning or weaker financing.

    Complementing this is the “Europe’s Mission on Cancer,” a large‑scale research and innovation initiative that aims to translate scientific advances into better‑organised cancer services. Under this mission, dozens of pilot projects are testing how comprehensive cancer centres, digital patient platforms, and cross‑border networks of experts can change day‑to‑day cancer care. For example, some pilots focus on virtual tumour boards where specialists from different countries jointly review complex cases, while others experiment with tele‑oncology consultations or remote monitoring after surgery. These pilots are designed not only to improve outcomes for individual patients but also to generate evidence on how to restructure oncology services in a way that is more resilient to delays and staff shortages.

    A central pillar of EU‑level reform is the push to standardise and speed up access to new cancer medicines. From 2025, the EU is introducing “Joint Clinical Assessments” (JCA) for all newly authorised oncology drugs and advanced therapies, such as cell and gene therapies. Under JCA, a single clinical assessment is produced for each drug, which all member states can then use as a basis for their national pricing and reimbursement decisions. This reduces duplication of work and is expected to shorten the time between an EU‑wide marketing authorisation and a drug’s availability in national health systems. The goal is to prevent situations in which patients in one country wait months or even years longer than those in another to receive the same innovative treatment, even though the drug is approved across the bloc.

     At the country level, several European health systems are reorganising their cancer‑service architecture around “National Comprehensive Cancer Centres” (NCCC) and regional networks. These centres are designed to combine high‑volume clinical activity, advanced diagnostics, clinical trials, and specialised expertise in one place, while maintaining links with smaller hospitals and community services. In practice, this means that complex surgeries, radiotherapy intensification, or rare‑tumour treatments are concentrated in a limited number of well‑equipped centres, while local hospitals handle more routine follow‑up and basic diagnostics. The underlying logic is that concentrating expertise improves quality and efficiency, while coordinated networks help rural or underserved regions access the same standard of care without forcing every small hospital to replicate ultra‑specialised infrastructure.

    Cross‑brder collaboration is becoming another key feature of the reform landscape. The EU is supporting the creation of the “EUNetCCC” network, which links comprehensive cancer centres across member states to share best practices, training, and even patient referrals. For instance, a patient in a smaller EU country might receive a second opinion or a complex targeted therapy through a partner comprehensive cancer centre in another member state, while remaining under the coordination of their home‑country team. This approach is especially important for rare cancers or highly specialised treatments, where expertise is naturally more thinly distributed. Over time, such networks could help reduce geographic inequalities and ensure that a patient’s prognosis depends less on where they live and more on the biology of their tumour.

     Digitalisation and data‑driven planning are equally central to the post‑pandemic reform agenda. Many European governments are expanding national cancer registries and linking them to EU‑level systems like the European Cancer Information System (ECIS), which allows real‑time or near‑real‑time monitoring of incidence, stage at diagnosis, treatment patterns, and survival. This surveillance capacity helps policymakers see where backlogs are growing, where certain tumour types are being diagnosed too late, or where inequalities between regions or social groups are widening. On top of that, the broader European Health Data Space (EHDS) is meant to make it easier for authorised clinicians and researchers to access anonymised health data across borders, which can be used to adjust workloads, forecast treatment demand, and design more efficient referral pathways.

    Within hospitals, reforms are also targeting how and where care is delivered. Many countries are experimenting with tele‑oncology consultations, virtual follow‑up visits, and remote monitoring tools that allow patients to report symptoms from home while reducing the need for frequent hospital trips. For some cancer types, such as early‑stage breast or colorectal cancer, a “digital‑first” or hybrid model is being tested, where routine check‑ups are conducted online while in‑person visits are reserved for key decision points like treatment initiation or toxicity assessment. These changes not only help clear backlogs by freeing up clinic space but also improve access for patients who live far from major cancer centres or who have mobility or caregiving constraints.

     Workforce planning and upskilling are another critical strand of the reform effort. Studies suggest that Europe will face a growing shortage of healthcare professionals, including oncologists, radiologists, pathologists, and cancer nurses, while the number of new cancer cases continues to rise. To address this, some countries are restructuring training programmes, expanding the roles of non‑physician specialists, and using digital decision‑support tools to help generalists manage more routine aspects of cancer care under supervision. For example, AI‑assisted tools for interpreting imaging or pathology slides can increase diagnostic throughput without necessarily requiring more staff, allowing human specialists to focus on more complex cases. At the same time, EU‑funded projects are promoting standardised training curricula and cross‑border exchanges of oncology professionals, so that skill‑shortage regions can benefit from shared expertise and temporary staffing solutions.

    Prevention and early detection remain a visible priority, especially after the pandemic disrupted many screening programmes. Several European countries are now expanding or relaunching national screening for breast, cervical, and colorectal cancers, sometimes coupled with digital invitations, reminders, and home‑based tests (such as stool‑based kits for colorectal cancer). The reform logic here is clear: catching cancer earlier not only improves survival but also reduces the need for highly intensive, resource‑heavy treatments later on. Some countries are also strengthening primary‑care involvement, training general practitioners to recognise early cancer symptoms more quickly and to refer suspected cases through streamlined “rapid‑diagnosis” pathways, similar to the 28‑day standard seen in the UK but adapted to local contexts.

    Finally, the reforms are increasingly framed in terms of equity and social justice. Reports from the European Commission and the European Court of Auditors repeatedly highlight that access to cancer care is uneven across regions, income groups, and ethnic communities, and that waiting times and treatment‑start delays are often longest for the most disadvantaged. As a result, many new cancer‑service models explicitly include measures to monitor and reduce disparities such as targeted outreach in underserved areas, language‑accessible information, and financial support for transportation or lost income during treatment. This equity‑focused lens means that, in theory, the goal of reform is not only to make cancer services faster but also to make them fairer, so that no group is systematically left behind in the race to recover from the pandemic‑related backlog.

     Across these strands EU‑wide coordination, national‑level restructuring, digital tools, workforce adaptation, and equity‑driven policies European countries are gradually reshaping how cancer care is organised and delivered. The reforms are not yet complete, and many countries still struggle with long waiting times, uneven access, and workforce shortages. Yet the direction is unmistakable: instead of treating the pandemic‑induced backlog as a one‑off crisis, European policymakers are using it as a catalyst to redesign cancer services in a way that is more coordinated, more resilient, and more attuned to the realities of 21st‑century cancer care.